Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million
Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...
Brand Name : CanGaroo RM
Molecule Type : Small molecule
Upfront Cash : $35.0 million
November 09, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : HighCape Capital
Deal Size : $26.2 million
Deal Type : Private Placement
Elutia Announces Private Placement for Proceeds up to $26 Million
Details : The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Brand Name : CanGaroo
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : HighCape Capital
Deal Size : $26.2 million
Deal Type : Private Placement
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million
Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...
Brand Name : CanGaroo
Molecule Type : Small molecule
Upfront Cash : $35.0 million
September 18, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Lead Product(s) : Minocycline Hydrochloride,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : H.C. Wainwright & Co.
Deal Size : $15.0 million
Deal Type : Public Offering
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
Details : Citius intends to use the net proceeds for pre-clinical and clinical development of its product candidates, including Mino-Wrap, a malleable, bio-absorbable film impregnated with minocycline and rifampin used in patients that elect to undergo reconstruct...
Brand Name : Mino-Wrap
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 04, 2023
Lead Product(s) : Minocycline Hydrochloride,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : H.C. Wainwright & Co.
Deal Size : $15.0 million
Deal Type : Public Offering
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial Envelope
Details : CanGaroo RM Antibacterial Envelope contains the antibiotics rifampin and minocycline, which have been shown in preclinical testing to reduce bacterial colonization on the envelope.
Brand Name : CanGaroo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Mino-Wrap is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander infections following breast reconstructive surgeries. Some next steps for Mino-Wrap development include designing and executing a large animal study...
Brand Name : Mino-Wrap
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 09, 2020
Lead Product(s) : Minocycline Hydrochloride,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dapsone,Doxycycline,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Research found that eight-week course of the proven leprosy drug dapsone combined with doxycycline and rifampin is effective in improving symptoms in 98% of patients suffering from chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 28, 2020
Lead Product(s) : Dapsone,Doxycycline,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Minocycline Hydrochloride,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult
Details : Mino-Wrap is a novel approach to reducing post-operative infections associated with surgical implants. Mino-Wrap is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructi...
Brand Name : Mino-Wrap
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 04, 2020
Lead Product(s) : Minocycline Hydrochloride,Rifampicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?